Mirae Asset Global Investments Co. Ltd. Purchases 124,138 Shares of Pfizer Inc. $PFE

Mirae Asset Global Investments Co. Ltd. boosted its position in Pfizer Inc. (NYSE:PFE) by 14.7% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 968,032 shares of the biopharmaceutical company’s stock after acquiring an additional 124,138 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Pfizer were worth $24,665,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently bought and sold shares of PFE. Brighton Jones LLC lifted its position in shares of Pfizer by 1,282.4% during the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock worth $17,677,000 after purchasing an additional 618,117 shares during the last quarter. Revolve Wealth Partners LLC increased its position in Pfizer by 12.5% in the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock worth $498,000 after buying an additional 2,087 shares during the period. B.O.S.S. Retirement Advisors LLC lifted its holdings in shares of Pfizer by 5.0% during the second quarter. B.O.S.S. Retirement Advisors LLC now owns 11,450 shares of the biopharmaceutical company’s stock worth $278,000 after buying an additional 543 shares during the last quarter. Woodward Diversified Capital LLC boosted its position in shares of Pfizer by 75.4% in the second quarter. Woodward Diversified Capital LLC now owns 29,055 shares of the biopharmaceutical company’s stock valued at $704,000 after acquiring an additional 12,491 shares during the period. Finally, Cantor Fitzgerald Investment Advisors L.P. boosted its position in shares of Pfizer by 1.9% in the second quarter. Cantor Fitzgerald Investment Advisors L.P. now owns 522,094 shares of the biopharmaceutical company’s stock valued at $12,656,000 after acquiring an additional 9,592 shares during the period. 68.36% of the stock is currently owned by institutional investors.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer agreed to pay up to $530M for a non?exclusive license to Novavax’s Matrix?M adjuvant to boost its vaccine pipeline — a near?term product development catalyst that can lift vaccine margins and pipeline value. Pfizer Inks $530M Deal for Novavax Matrix?M Adjuvant Technology
• Positive Sentiment: Analysis framing Pfizer as a “high?yield pharma at a turning point” highlights valuation appeal and potential upside if pipeline execution and buybacks/dividends continue — a positive narrative for income and value investors. Pfizer: A High?Yield Pharma At A Turning Point
• Neutral Sentiment: Pre?earnings coverage summarizes Wall Street’s Q4 and key metric estimates — useful for gauging upcoming guidance/beat?miss risk ahead of Pfizer’s results. Ahead of Pfizer (PFE) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics
• Neutral Sentiment: A primer on seven companies Pfizer owns provides background on asset mix and diversification — helpful for longer?term fundamental analysis but less likely to move the stock immediately. 7 Companies Owned by Pfizer
• Negative Sentiment: Zacks Research reportedly downgraded Pfizer to a “strong sell,” which can pressure sentiment and trigger short?term outflows even if the broader fundamentals remain intact. Zacks Downgrades Pfizer
• Negative Sentiment: The CMS named multiple Pfizer drugs for a round of Medicare price negotiations — a direct regulatory risk that could compress future pricing and revenue for affected medicines. CMS Names Pfizer, Eli Lilly, and AbbVie Drugs for Third Medicare Price Talks
• Negative Sentiment: Coverage shows Pfizer underperforming peers recently, indicating relative weakness that can weigh on multiple?day momentum and investor sentiment. Pfizer Inc. stock underperforms Wednesday when compared to competitors
• Negative Sentiment: Reporting indicates Pfizer is reshaping its portfolio (ViiV exit) amid a White House drug?pricing push — strategic but potentially revenue?dilutive and signaling near?term uncertainty around growth composition. Pfizer Reshapes Portfolio As ViiV Exit Meets White House Pricing Deal

Pfizer Stock Up 0.9%

Shares of PFE opened at $26.08 on Friday. The company has a quick ratio of 0.97, a current ratio of 1.28 and a debt-to-equity ratio of 0.62. The company has a 50-day moving average price of $25.49 and a two-hundred day moving average price of $25.02. The stock has a market cap of $148.28 billion, a price-to-earnings ratio of 15.16 and a beta of 0.47. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $27.69.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.79 by $0.08. The business had revenue of $16.65 billion during the quarter, compared to analysts’ expectations of $16.94 billion. Pfizer had a return on equity of 20.17% and a net margin of 15.65%.Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. Equities analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, January 23rd will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.6%. The ex-dividend date of this dividend is Friday, January 23rd. Pfizer’s dividend payout ratio (DPR) is currently 100.00%.

Analyst Upgrades and Downgrades

Several research firms recently commented on PFE. Sanford C. Bernstein reiterated a “market perform” rating and set a $30.00 target price on shares of Pfizer in a research note on Friday, October 31st. HSBC reaffirmed a “buy” rating and set a $29.00 price objective on shares of Pfizer in a research report on Wednesday, December 10th. Cantor Fitzgerald increased their target price on shares of Pfizer from $24.00 to $27.00 and gave the company a “neutral” rating in a research note on Tuesday. Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a research note on Thursday, January 22nd. Finally, Bank of America reduced their price objective on Pfizer from $29.00 to $28.00 and set a “neutral” rating for the company in a research report on Monday, December 15th. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $28.06.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.